BostonGene

Comprehensive molecular tumor profiling to guide precision treatment

Verified partnerTakes insuranceFinancial aid availableFeatured

Testing5 offerings

Your records go with you, in one click

Comprehensive molecular and immune tumor profiling to guide precision treatment. OpenCancer pre-fills the BostonGene intake from your records and carries your consent, so nothing gets retyped and nothing moves without your say-so.

Why BostonGene exists

BostonGene provides comprehensive molecular and immune profiling of your tumor, combining whole-exome and RNA sequencing with an AI-powered analysis to identify the biomarkers, mutations, and immune features most relevant to your treatment. The goal is to match each patient to the therapies and trials with the highest likelihood of response.

Comprehensive report to your oncologistCLIA-certified / CAP-accredited laboratoryAI-powered analysis

1
Sample from tissue or blood
Profiling runs from a tumor tissue sample or, for liquid biopsy, a standard blood draw.
2
Whole-exome + RNA sequencing
DNA and RNA are sequenced for a complete molecular and immune picture of the tumor.
3
AI-powered analysis
Biomarkers, mutations, and immune features are analyzed and interpreted.
4
Actionable report
Your oncologist receives matched therapy and trial options with the supporting evidence.

Prefer the source? BostonGene's own site has more.

Connect with BostonGene via OpenCancer

Direct intake integration: your records, case summary, and consent flow to BostonGene in one step — nothing retyped, nothing sent without your sign-off.

Connect now →

Check your coverage

See if your insurance covers this and estimate out-of-pocket cost.

Check coverage →

What they offer

Testing· 5

Target immunotherapies with the highest likelihood of response
Provide an integrated profile of the disease at maximum depth to identify novel personalized treatment options and guide strategy and decisions
Map the tumor microenvironment, especially cancer heterogeneity and immune cell proliferation
Uncover any abnormalities in the transcriptome that may inform treatment
Uncover what genetic coding is driving my cancer, especially those variants of interest that can be targeted for treatment

Coverage, insurance & cost

The fastest way to know what you'll pay: check your coverage with your plan. Below is what we know about how BostonGene handles billing.

Insurance

Accepted

Financial aid

Available

Prior auth

Required

In-network carriers

MedicareBlue Cross Blue ShieldUnitedHealthcareAetna

Build a personalized cost estimate

Ask about this service

Answers grounded in BostonGene's details here. Educational only; your oncologist directs treatment.

Who this is for

Cancer types served

bladderbrainbreastcolorectalesophagealgastricleukemialunglymphomamelanomaovarianpancreaticprostatesarcomasolid tumors

Most relevant with

EGFRKRASALKBRAFHER2PD-L1MSITMB

Sample: A stored tissue block from a prior biopsy.

How to ask your doctor about this

Questions to bring to your oncologist. This page is general information, not medical advice.

Would comprehensive molecular profiling change my treatment options?
Do we have enough tissue, or would a liquid biopsy be better for me?
Could this identify clinical trials I would be eligible for?

Common questions in this category

Based on what other patients have asked.

When is a pet/ct scan advised for a new breast cancer diagnosis

Breast Cancer

Does the specific variant of the CHEk2 mutation make a difference? I have the Ashkenazi Founder variant.

Is the CHEK2 mutation related to prostate cancer

What lifestyle changes are recommended for Prostate - Early Stage patients

Prostate - Early Stage

What should I know as a newly diagnosed CRC patient

Colorectal Cancer

What should I ask my oncologist after a new diagnosis

Also consider

Other providers in similar categories.

Tempus

5 offerings

Tempus xT is a comprehensive genomic profiling test combining DNA and RNA sequencing to identify actionable mutations.

Foundation Medicine

4 offerings

FoundationOne CDx is an FDA-approved comprehensive genomic profiling test that analyzes 324 genes to identify clinically relevant genomic alterations.